Join us on December 14 for our Patient-Focused Sessions on Multiple Myeloma, taking place in Charlotte, NC! 

×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Events
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Bladder Cancer

Hannah Slater
The FDA has granted a priority review to a supplemental biologics license application (sBLA) for Keytruda (pembrolizumab), an anti-PD-1 immunotherapy, for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC), according to Merck, the drug’s manufacturer.
Katie Kosko
The oral medication Balversa (erdafitinib) shows promise in patients who have FGFR3 gene alterations.
Jessica Skarzynski
Here are the top 5 CURE stories for July 2019.
Alexandra Guadagno
Genomic distinctions between bladder cancer variances are revealed through rapid autopsy, according to one study, and may help push forward bladder cancer research.
Kristie L. Kahl
Karen, who received her bladder cancer diagnosis in 2010, was faced with a similar challenge after her husband was diagnosed with the same disease just six years later.
Kristie L. Kahl
In this week’s episode of the “CURE Talks Cancer” podcast, we spoke with a bladder cancer survivor turned caregiver about the advice she would give her newly-diagnosed self.
Katie Kosko
A medical oncologist discusses the findings of three clinical trials presented during the 2019 American Society of Clinical Oncology Annual Meeting.
Bladder Cancer Advocacy Network
The Bladder Cancer Advocacy Network announced the recipient of its prestigious Bladder Cancer Research Innovation Award. 
Katie Kosko
Compared with single-agent therapy, the combination of Yervoy and Opdivo showed a 38% overall response rate.
Kristie L. Kahl
After progressing on prior therapy, 44% of patients with locally advanced or metastatic urothelial cancer who were treated with enfortumab vedotin demonstrated a response to treatment, according to phase 2 study findings.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×